Bio News
In a clinical trial involving 12 patients with XLRS, the gene therapy JWK002 improved visual acuity by 10.8 letters, and the results were published in NEJM. Over 52 weeks, retinoschisis cavities closed without drug-related adverse events, while central retinal thickness (CRT) decreased by an average of 437.7 μm. JWK002 has now completed patient enrollment for a phase 2 clinical trial, and further development is underway.
BIOBOOK TEAM
biobookmedia@biobook.co.krParagon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
Pfizer Signs $500 Million Protein Degrader Deal With Enodia
